<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03981536</url>
  </required_header>
  <id_info>
    <org_study_id>AP101-01</org_study_id>
    <nct_id>NCT03981536</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>A Multicenter, Open Label, Single-Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AL-S Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AL-S Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single ascending doses of AP-101 will be administered by intravenous (IV) infusion
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With One or More Non-Serious Adverse Events (AEs) or Any Serious AEs (SAEs)</measure>
    <time_frame>Baseline up to day 84</time_frame>
    <description>A clinical trial AE is any untoward medical event associated with the use of a drug or drug delivery system in humans, whether or not it is considered related to that drug or drug delivery system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormalities in vital signs, clinical laboratory assessments, physical or neurological examinations, or electrocardiograms (ECGs)</measure>
    <time_frame>Baseline up to day 84</time_frame>
    <description>Vital signs include blood pressure, pulse rate, and body temperature</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Drug Concentration (Cmax)</measure>
    <time_frame>Baseline up to day 84</time_frame>
    <description>In serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Drug Concentration (Tmax)</measure>
    <time_frame>Baseline up to day 84</time_frame>
    <description>In serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve (AUC)</measure>
    <time_frame>Baseline up to day 84</time_frame>
    <description>In serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Concentrations in Cerebrospinal Fluid (CSF)</measure>
    <time_frame>Screening, and at either 1 hour, 4 hours, 24 hours, 48 hours, 72 hours, or 168 hours</time_frame>
    <description>Taken at screening, and then only one sample per participant post-dose, in the higher level doses</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>AP-101: Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AP-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AP-101: Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AP-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AP-101: Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AP-101</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AP-101</intervention_name>
    <description>Administered by intravenous infusion (IV)</description>
    <arm_group_label>AP-101: Dose Level 1</arm_group_label>
    <arm_group_label>AP-101: Dose Level 2</arm_group_label>
    <arm_group_label>AP-101: Dose Level 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All participants must adhere to contraception restrictions

          -  Female patients of non-childbearing potential due to:

               1. Menopause: spontaneous amenorrhea for at least 12 months not induced by a medical
                  conditions such as anorexia nervosa and not taking medications that induced the
                  amenorrhea (e.g., oral contraceptives, hormones, gonadotropin releasing hormones,
                  anti-estrogens, selective estrogen receptor modulators, or chemotherapy)

               2. Surgical sterilization

          -  Have possible, probable, probable laboratory supported or definite and definite
             familial laboratory-supported ALS in accordance with the El-Escorial criteria

          -  Have familial or sporadic ALS.

          -  With onset of ALS symptoms, specifically onset of muscle weakness within past 48
             months

          -  Have slow vital capacity (SVC) of (greater than or equal to) ≥60%

          -  If on riluzole, must be on a stable dose

          -  If on edaravone, must have completed 2 cycles and are expected to remain on the same
             dose throughout the study

          -  Able to provide informed consent. If the patient is not able to provide written
             consent due to aggravation of disease condition, written informed consent may be
             provided by a legally authorized representative

          -  Have venous access sufficient to allow for blood sampling

          -  Have clinical laboratory test results within normal reference range for the population
             or study site, or results with acceptable deviations that are judged to be not
             clinically significant

        Exclusion Criteria:

          -  Are currently enrolled in, or discontinued from, within the last 30 days, a clinical
             trial involving an investigational drug or device or off-label use of a drug or
             device, or any other type of medical research judged not to be scientifically or
             medically compatible with this study

          -  Have previously completed or withdrawn from this study

          -  Have a history or presence of medical illness including, but not limited to, any
             cognitive, cardiovascular, hepatic, hematological, renal, endocrine, or psychiatric,
             or any clinically significant laboratory abnormality that indicates a medical problem
             that would preclude study participation

          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human
             HIV antibodies

          -  Show evidence of hepatitis C and/or positive hepatitis C antibody

          -  Show evidence of hepatitis B and/or positive hepatitis B surface antigen

          -  Are women who are lactating.

          -  Have undergone a tracheostomy unless it was removed at least 6 months prior

          -  Are on feeding tube, unless the insertion of a feeding tube is considered prophylactic

          -  Are on nasal intermittent positive pressure ventilation (NIPPV) &gt;4 hours per day or at
             the discretion of the medical monitor

          -  Have undergone stem cell therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>AL-S Pharma SA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Director: AL-S Pharma SA</last_name>
    <phone>3176517036</phone>
    <email>choruspharma@lists.lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>London Health Sciences Centre, University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chisten Shoesmith</last_name>
      <phone>519-685-8500</phone>
      <email>Christen.Shoesmith@lhsc.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Christine Piechowicz</last_name>
      <email>Christine.Piechowicz@lhsc.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Christen Shoesmith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre, Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorne Zinman</last_name>
      <phone>416-480-6100</phone>
      <email>lorne.zinman@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Shirley Pham</last_name>
      <phone>416-480-6100</phone>
      <email>Shirley.Pham@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Lorne Zinman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute &amp; Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxime Berube</last_name>
      <phone>514-398-6644</phone>
      <email>maximeberube@sympatico.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kristiana Salmon</last_name>
      <email>kristiana.salmon@mcgill.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Maxime Berube</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Familial Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Sporadic Amyotrophic Lateral Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

